Nantahala Capital Management
Tracked across 4 events · 25 articles · First seen Apr 14, 2026 · Last active Sep 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Nantahala Capital Management led the private placement as the new institutional investor, demonstrating confidence in Femasys' strategy and technologies.
Aug 07, 2026 · 6 articles
Business
Lisata Therapeutics acquired Marea Therapeutics, a clinical-stage biotechnology company developing next-generation medicines for cardioendocrine diseases, in a stock-for-stock transaction. All of Marea's outstanding equity interests were exchanged for 1,793,129 shares of Lisata common stock and…
Impact: Participated in the oversubscribed private placement financing.
Sep 17, 2026 · 6 articles
Business
Impact: Nantahala Capital Management is one of the new investors participating in the $350 million private placement financing for the combined Galera Therapeutics and Obsidian Therapeutics, Inc. entity.
Apr 14, 2026 · 7 articles
Business
Impact: Nantahala Capital Management is a participating investor in the private placement, providing capital to Quoin Pharmaceuticals.
Aug 28, 2026 · 6 articles
30
Nantahala Capital Management participated in financing Lisata TherapeuticsLisata Acquires Marea,...
ERGEN INTELLIGENCE
Track Nantahala Capital Management live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard